Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision lossCompanies: Roche HoldingBasel, 10 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swelling in the back of the eye due to retinal fluid) with vamikibart treatment. The data were presented at the American Academy of Ophthalmology 2026 Annual Meeting (AAO 2026) in New Orleans, LA.1
- FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancerCompanies: Roche HoldingBasel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. This approval marks the twelfth indication for Tecentriq in the US.
- Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRCCompanies: Roche HoldingRoche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC. Roche will preconfigure the instruments and train local laboratory technicians before deploying them to Bunia. INSP will conduct...
- Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditionsCompanies: Roche HoldingBasel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust anatomical improvements in untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes.1-3
- Roche launches newborn screening test for three severe genetic conditionsCompanies: Roche HoldingThis test expands Roche's early diagnostics portfolio by screening for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) simultaneously. Catching these conditions shortly after birth empowers clinicians to choose life-changing...
- Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance CompetitionCompanies: PfizerRoche HoldingBoost ROI with question-led libraries, reproducible synthesis, validated assays, interoperable data, AI feedback loops, partnerships, and early planning for IP, regulation, supply and talent
- Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)Companies: Roche HoldingBasel, 23 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function.5,6 Sefaxersen is a once-monthly subcutaneous injection designed to enable self-administration for people with IgAN. The safety and tolerability profile of sefaxersen was consistent with previously reported data, with no new safety signals identified.
- Änderung im Verwaltungsrat von RocheCompanies: Roche HoldingDer Verwaltungsrat der Roche Holding AG hat beschlossen, Herrn Dr. Christophe Weber, ehemaliger CEO von Takeda Pharmaceuticals, der Generalversammlung am 9. März 2027 zur Neuwahl in den Verwaltungsrat vorzuschlagen.
- Change in Roche’s Board of DirectorsCompanies: Roche HoldingRoche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche’s Annual General Meeting on March 9, 2027.
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesityCompanies: Roche HoldingBasel, 22 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity. In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Patients receiving the highest titrated dose (24 mg) achieved an HbA1c reduction of 2.65% (from a baseline HbA1c of 8.1%). Furthermore, 90% of patients in the 24 mg cohort reached an HbA1c level of ≤6.5% (diagnostic threshold for T2D) and 62% achieved normoglycemia (HbA1c < 5.7%), restoring blood glucose levels to a non-diabetic range. The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5% without a demonstrable plateau.
- Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key PlayersCompanies: DexcomGarmin Ltd.Medtronic plcRoche HoldingSamsung Electronics"Wearable Biosensors Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering. According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions, and the increasing adoption of personalized healthcare solutions. Wearable biosensors are sophisticated devices that enable real-time tracking of physiological parameters, providing critical data for early disease detection and remote patient management. The global wearable biosensors market is undergoing a profound structural transformation as the healthcare industry shifts from episodic, clinic-based care toward continuous, proactive health management. This evolution is being catalyzed by the rapid miniaturization of sensing technologies and the integration of advanced data analytics and artificial intelligence into consumer wearables. The industry is witnessing a significant transition from simple activity trackers toward medical-grade diagnostic devices that can monitor complex biomarkers like glucose, blood pressure, and cardiac rhythms with high precision. Furthermore, the integration of wearable biosensors with digital health and telemedicine platforms is creating a seamless ecosystem for remote patient monitoring and virtual care delivery. This dynamic shift ensures sustained demand for non-invasive, user-friendly sensing solutions that empower individuals and healthcare providers with actionable health insights, ultimately improving clinical outcomes and reducing healthcare costs. Market Segmentation The global wearable biosensors market is segmented by biomarker type (glucose monitoring, heart rate and cardiac biomarkers, blood oxygen [SpO2] monitoring, blood pressure monitoring, lactate and performance biomarkers, and other biomarkers), product type/form factor (smartwatches, fitness bands, continuous glucose monitoring devices, wearable ECG monitors, smart patches, smart rings, and smart clothing), application (clinical and medical, fitness and wellness, and sports and performance monitoring), end-user (hospitals and clinics, home care settings, fitness and sports organizations, individual consumers, and research institutions), and geography. The study evaluation includes industry competitors and analyzes the market at the country level. Based on Biomarker Type By biomarker type, the glucose monitoring segment is expected to hold the largest share of the global wearable biosensors market in 2026. This dominance is attributed to the high and rising prevalence of diabetes globally and the widespread adoption of continuous glucose monitoring (CGM) systems that eliminate the need for frequent finger-prick testing. Conversely, the heart rate and cardiac biomarkers segment is projected to register significant growth, driven by the increasing integration of ECG and heart rate variability (HRV) sensing into consumer smartwatches, enabling early detection of arrhythmias and other cardiovascular conditions. Furthermore, the lactate and multi-analyte biosensors segments are projected to register the highest CAGR during the forecast period, fueled by the growing demand for performance optimization in sports and the development of non-invasive sensors for comprehensive metabolic health tracking. Based on Product Type / Form Factor By product type/form factor, the smartwatches with integrated biosensors segment is expected to hold the largest share of the global wearable biosensors market in 2026. Smartwatches have become the primary platform for health monitoring due to their high consumer acceptance, multi-functionality, and the continuous addition of medical-grade sensors by leading tech companies. Meanwhile, the continuous glucose monitoring devices segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the shift toward proactive diabetes management and the expansion of CGM use among non-insulin-dependent patients and health-conscious individuals. Additionally, smart patches and smart rings are emerging as high-growth segments, offering discrete and specialized monitoring for clinical and wellness applications. Based on Application By application, the clinical and medical segment is expected to hold the largest share in 2026. The increasing use of wearable biosensors for chronic disease management, post-operative monitoring, and clinical trials drives this segment's leadership. Within this segment, remote patient monitoring (RPM) is a major growth catalyst. Conversely, the fitness and wellness segment is projected to register a steady growth rate, driven by the increasing consumer focus on preventive health and the popularity of activity and sleep tracking. The sports and performance monitoring segment is also witnessing rapid expansion as professional athletes and fitness enthusiasts adopt biosensors to optimize training and recovery through data-driven insights. Based on End-User By end-user, the hospitals and clinics segment is expected to hold the largest share in 2026, reflecting the primary role of healthcare providers in prescribing and managing medical-grade wearable sensors for patient care. Conversely, the home care settings segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the global trend toward decentralized healthcare and the increasing preference for monitoring patients in their home environments to improve comfort and reduce hospital readmissions. The individual consumers segment also remains significant, as more people purchase wearables for personal health and fitness tracking. Geographic Analysis In 2026, North America is expected to account for the largest share of the global wearable biosensors market. The region's leadership is underpinned by a highly advanced healthcare infrastructure, high levels of digital health literacy, and the presence of industry leaders such as Abbott, Dexcom, Apple, and Medtronic in the United States. Furthermore, the early adoption of remote patient monitoring and a favorable reimbursement landscape for digital health technologies contribute to the market's dominance. Key companies in the North America market include Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), Apple Inc. (U.S.), Medtronic plc (Ireland), Garmin Ltd. (U.S.), Google LLC (Fitbit - U.S.), Masimo Corporation (U.S.), VitalConnect, Inc. (U.S.), and Biolinq Inc. (U.S.). Asia-Pacific is projected to witness the fastest growth during the forecast period. This expansion is primarily driven by increasing healthcare expenditure, the rapid expansion of the middle-class population, and the high penetration of smartphones and wearable devices in China, India, and Japan. Furthermore, the rising burden of chronic diseases in the region and government initiatives to promote digital health are significant catalysts. Key companies in the Asia-Pacific market include Samsung Electronics Co., Ltd. (South Korea) and various emerging local MedTech startups. Europe remains a critical market for wearable biosensors, characterized by a strong focus on preventive healthcare and the implementation of robust medical device regulations. European countries are increasingly adopting wearable sensors to address the healthcare needs of an aging population and to improve the efficiency of public health systems. The region's focus on data privacy and security is driving the demand for sensors that comply with strict GDPR and MDR standards. Key companies in the Europe market include F. Hoffmann-La Roche Ltd. (Switzerland), Oura Health Ltd. (Finland), and Empatica Inc. (U.S./Italy). Latin America is an emerging market for wearable biosensors, driven by the modernization of healthcare facilities and the increasing adoption of consumer health technologies in Brazil and Mexico. The region is seeing a shift toward more accessible health monitoring solutions as enterprises and individuals seek to manage chronic conditions more effectively. The Middle East & Africa region is experiencing growing interest in wearable biosensors as part of national digital health transformation strategies, particularly in the UAE and Saudi Arabia. Investments in high-tech healthcare infrastructure and the adoption of AI-driven health solutions are expected to be major drivers of market growth in the region. Key Players The key players operating in the global wearable biosensors market include:
- Nucleic Acid Isolation and Purification Market Forecasts Growth from $5.41B (2026) to $10.52B by 2035, Profiling Roche, Promega, Macherey-Nagel & 7 Other Key PlayersCompanies: Roche HoldingNGS, personalized medicine, RNA therapeutics and chronic disease testing are driving demand for automated, magnetic and microfluidic purification solutions.